Biotechnology pioneer Enantis is advancing the development of FGF10-STAB, a hyper-stable fibroblast growth factor, to provide innovative treatment solutions for patients with severe forms of Acute Respiratory Distress Syndrome (ARDS). ARDS is a life-threatening condition characterized by rapid onset of widespread inflammation in the lungs, often requiring mechanical ventilation. With a high mortality rate and no effective treatment available, there is an urgent need for new therapies that target the underlying causes and support recovery.
FGF10-STAB stands out as a promising candidate due to its ability to promote tissue regeneration, reduce inflammation, and enhance alveolar repair. Its unique hyper-stable properties ensure prolonged activity and effectiveness, even under challenging conditions, making it an ideal candidate for addressing the needs of critically ill patients. The project focuses on determining the most effective delivery method—such as aerosol inhalation, endotracheal intubation, or carriers containing FGF10-STAB—and tailoring the solution for ventilated patients experiencing severe ARDS progression.
Collaborating with members of the CZECRIN Pneumo platform, including doc. MUDr. Vladimír Koblížek, Ph.D. (FN Hradec Králové), prof. MUDr. Miloslav Marel, CSc. (FN Motol), MUDr. Petr Jakubec, Ph.D. (FN Olomouc), and MUDr. Ondřej Fibigr (FN Plzeň), Enantis is refining its approach by incorporating direct clinical feedback. These experts are providing essential guidance on formulating FGF10-STAB, identifying target patient groups, and designing experiments that demonstrate the solution’s efficacy convincingly.
Initiated in November 2024 with its first meeting on November 26th, the project continues into 2025, with further consultations planned for Q1. The ultimate goal is to finalize a clinical formulation of FGF10-STAB and progress to First in Human clinical trials to validate its safety and efficacy. “ARDS is a devastating condition that leaves clinicians with few effective tools, and the urgency to innovate has never been greater,” said Marek Atanasčev, CEO of Enantis. “Our work on FGF10-STAB reflects our commitment to bridging groundbreaking research with real-world clinical needs. By collaborating with leading experts through the CZECRIN Pneumo platform, we aim to develop a therapy that can transform outcomes for ARDS patients and set a new standard of care.”
This project underscores Enantis’ mission to combine scientific excellence with meaningful clinical applications. FGF10-STAB exemplifies the company’s dedication to addressing complex challenges in respiratory medicine and beyond.